Skip to main content
SpringerLink
Log in

CANCER IMMUNOTHERAPY

A decade of CAR T cell evolution

  • News & Views
  • Published:

From Nature Cancer

View current issue Submit your manuscript

Two of the first patients with cancer treated with chimeric antigen receptor-modified (CAR) T cells have been cancer free for a decade. A new study uses single-cell sequencing technologies to provide a window into the evolution of their CAR T cells over the course of the ten-year remission period.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1: Two patients with chronic lymphocytic leukemia were among the first recipients of CAR T cells.

References

  1. Melenhorst, J. J. et al. Nature 602, 503–509 (2022).

    Article  CAS  Google Scholar 

  2. Porter, D. L., Levine, B. L., Kalos, M., Bagg, A. & June, C. H. N. Engl. J. Med. 365, 725–733 (2011).

    Article  CAS  Google Scholar 

  3. Kalos, M. et al. Sci. Transl. Med. 3, 95ra73 (2011).

    Article  CAS  Google Scholar 

  4. Fraietta, J. A. et al. Nature 558, 307–312 (2018).

    Article  CAS  Google Scholar 

  5. Grupp, S. A. et al. N. Engl. J. Med. 368, 1509–1518 (2013).

    Article  CAS  Google Scholar 

  6. Abramson, J. S. et al. Lancet 394, 839–852 (2020).

    Article  Google Scholar 

  7. Locke, F. L. et al. Lancet Oncol. 20, 31–42 (2019).

    Article  CAS  Google Scholar 

  8. Munshi, N. C. et al. N. Engl. J. Med. 384, 705–716 (2021).

    Article  CAS  Google Scholar 

  9. Fraietta, J. A. et al. Nat. Med. 24, 563–571 (2018).

    Article  CAS  Google Scholar 

  10. Deng, Q. et al. Nat. Med. 26, 1878–1887 (2020).

    Article  CAS  Google Scholar 

  11. Locke, F. L. et al. Blood Adv. 4, 4898–4911 (2020).

    Article  CAS  Google Scholar 

  12. Shouval, R. et al. J. Clin. Oncol. 40, 369–381 (2022).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA

    Marcela V. Maus

Authors
  1. Marcela V. Maus
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marcela V. Maus.

Ethics declarations

Competing interests

M.V.M. is an inventor on patents related to adoptive cell therapies, held by Massachusetts General Hospital and the University of Pennsylvania (some licensed to Novartis). M.V.M. holds equity in TCR2, Century Therapeutics, Genocea, Oncternal, and Neximmune, and has served as a consultant for multiple companies involved in cell therapies. Consultant for: Adaptimmune, Agenus, Allogene, Arcellx, Astellas, AstraZeneca, Atara, Bayer, BMS, Cabaletta Bio (SAB), Cellectis (SAB), CRISPR Therapeutics, EMD Serono, Genocea, In8bio (SAB), Intellia, GSK, Kite Pharma, Micromedicine/BendBio, Neximmune, Novartis, Oncternal, Sanofi, Synthekine, TCR2 (SAB), Tmunity, Werewolf and WindMIL (SAB). Speaker’s Bureau: none. Grant/Research support: Kite Pharma, Servier, Novartis Stockholder: Century Therapeutics, Genocea, Oncternal, TCR2, 2Seventy Bio. Board of Directors: 2Seventy Bio.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Maus, M.V. A decade of CAR T cell evolution. Nat Cancer 3, 270–271 (2022). https://doi.org/10.1038/s43018-022-00347-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s43018-022-00347-4

  • Springer Nature America, Inc.

This article is cited by

Search

Navigation